Study Design of the Global Prospective Hemolytic Disease of the Fetus and Newborn Registry (GERANIUM)

The authors aim to address significant gaps in understanding the safety and effectiveness of current management strategies for hemolytic disease of the fetus and newborn (HDFN) through the Global Prospective Hemolytic Disease of the Fetus and Newborn Registry (GERANIUM). This prospective, observational study will enroll approximately 175 alloimmunized pregnant individuals and collect longitudinal data on treatment patterns, clinical outcomes, and the impact of HDFN on both infants and their families over a two-year period post-birth. By providing real-world data, GERANIUM seeks to enhance knowledge of HDFN management and its long-term effects.